Nasopharyngeal Cancer Clinical Trials

16 recruiting

Nasopharyngeal Cancer Trials at a Glance

18 actively recruiting trials for nasopharyngeal cancer are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Guangzhou, Zhongshan, and Nanning. Lead sponsors running nasopharyngeal cancer studies include Sun Yat-sen University, German Society for Pediatric Oncology and Hematology GPOH gGmbH, and Fudan University.

Browse nasopharyngeal cancer trials by phase

Treatments under study

About Nasopharyngeal Cancer Clinical Trials

Looking for clinical trials for Nasopharyngeal Cancer? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Nasopharyngeal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Nasopharyngeal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Not Applicable

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Nasopharyngeal CancerNasopharyngeal CarcinomaStage III Nasopharyngeal Carcinoma AJCC v8+2 more
University of California, San Francisco66 enrolled1 locationNCT06682442
Recruiting
Phase 4

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Nasopharyngeal Cancer Recurrent
Coherus Oncology, Inc.100 enrolled13 locationsNCT06457503
Recruiting

Integrated Cancer Repository for Cancer Research

Breast CancerLiver CancerEsophageal Cancer+47 more
University of Nebraska999,999 enrolled45 locationsNCT02012699
Recruiting
Phase 2Phase 3

Trop2-targeted immunoPET Imaging of Solid Tumors

Liver CancerOvarian CancerCervical Cancer+11 more
RenJi Hospital400 enrolled1 locationNCT06851663
Recruiting
Phase 2

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

Nasopharyngeal Cancer
National University Hospital, Singapore50 enrolled1 locationNCT05305131
Recruiting

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

Prostate CancerNasopharyngeal CancerOther Cancer
National Cancer Centre, Singapore5,000 enrolled1 locationNCT04340024
Recruiting
Phase 3

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Nasopharyngeal CancerNasopharyngeal Cancinoma (NPC)
Sun Yat-Sen University Cancer Center580 enrolled19 locationsNCT06749899
Recruiting
Phase 2

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Nasopharyngeal Cancer
Maria Sklodowska-Curie National Research Institute of Oncology32 enrolled4 locationsNCT04875611
Recruiting
Phase 2

Adebrelimab and Chemoradiotherapy in High-risk LANPC

Nasopharyngeal CancerNasopharyngeal Carcinoma
Sun Yat-sen University50 enrolled4 locationsNCT06349889
Recruiting

Arabic PRO Measures for Head and Neck Cancer Radiotherapy.

Head and Neck CancerHead and Neck Squamous Cell CarcinomaHead and Neck Neoplasms+5 more
King Saud University125 enrolled1 locationNCT06662929
Recruiting

A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Liver CancerPancreatic CancerGastric Cancer+8 more
Zhujiang Hospital12,000 enrolled50 locationsNCT05638269
Recruiting
Phase 2

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Nasopharyngeal CancerNasopharyngeal CarcinomaNasopharynx Cancer+1 more
German Society for Pediatric Oncology and Hematology GPOH gGmbH57 enrolled31 locationsNCT06019130
Recruiting
Not Applicable

The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma

Nasopharyngeal CancerNasopharyngeal CarcinomaHypothyroidism
Jiangxi Provincial Cancer Hospital320 enrolled1 locationNCT06268600
Recruiting
Phase 2

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Nasopharyngeal Cancer
Fudan University198 enrolled1 locationNCT05628922
Recruiting
Not Applicable

Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients

Endoscopic SurgeryNasopharyngeal CarcinomaPrimary Napharyngeal Carcinama+1 more
Sun Yat-sen University228 enrolled5 locationsNCT03353467
Recruiting
Phase 3

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

ChemotherapyRadiotherapyNasopharyngeal Cancer+1 more
Sun Yat-sen University388 enrolled6 locationsNCT04453826
Recruiting

Utilization of 5HTT gene polymorphism as a prognostic indicator in cancer

cancer. We are recruiting patients with a known primary cancer of the following types: lymphoma, lung, gastrointestinal tumours, genitourinary tumours, hepatocellular cancer, breast, nasopharyngeal cancers). Adjustment for cancer type in the statisticall analysis will be done by including cancer type in the regression model.
University of Alexandria300 enrolled1 locationACTRN12610000028000
Recruiting
Phase 2

Gemcitabine and carboplatin induction chemotherapy followed by concurrent cisplatin and IMRT for locally advanced nasopharyngeal cancer

Locally advanced nasopharyngeal cancer
Peter MacCallum Cancer Centre30 enrolled1 locationACTRN12605000509662